Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, or Adalimumab in Patients with Active Psoriatic Arthritis and an Inadequate Response to Conventional Synthetic Dmards: A Randomized, Placebo-Controlled, Phase 3 Trial

被引：0

作者：

Mease, Philip J. ^{[1
,2
]}

Hall, Stephen ^{[3
,4
]}

FitzGerald, Oliver ^{[5
,6
]}

van der Heijde, Desiree ^{[7
]}

Merola, Joseph F. ^{[8
]}

Avila-Zapata, Francisco ^{[9
]}

Cieslak, Dorata ^{[10
]}

Graham, Daniela ^{[11
]}

Wang, Cunshan ^{[12
]}

Menon, Sujatha ^{[12
]}

Hendrikx, Thijs ^{[11
]}

Kanik, Keith ^{[12
]}

机构：

[1] Swedish Med Ctr, Seattle, WA USA

[2] Univ Washington, Seattle, WA 98195 USA

[3] Cabrini Hlth, Melbourne, Vic, Australia

[4] Monash Univ, Melbourne, Vic, Australia

[5] St Vincents Univ Hosp, Dept Rheumatol, Dublin, Ireland

[6] Univ Coll, Conway Inst, Dublin, Ireland

[7] Leiden Univ, Med Ctr, Leiden, Netherlands

[8] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA

[9] Ctr Multidisciplinario Desarrollo Especializado I, Merida, Yucatan, Mexico

[10] Poznan Univ, Poznan, Poland

[11] Pfizer Inc, Collegeville, PA USA

[12] Pfizer Inc, Groton, CT 06340 USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2983

引用

页数：4

共 50 条

[1] Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs: OPAL Broaden, a randomized, placebo-controlled, phase 3 trial
Mease, Philip
Hall, Stephen
FitzGerald, Oliver
van der Heijde, Desiree
Merola, Joseph
Avila-Zapata, Francisco
Graham, Daniela
Wang, Cunshan
Kanik, Keith
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB114 - AB114
[2] EFFICACY AND SAFETY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, OR ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS): A RANDOMISED, PLACEBO-CONTROLLED, PHASE 3 TRIAL
Mease, P. J.
Hall, S.
FitzGerald, O.
van der Heijde, D.
Merola, J. F.
Avila-Zapata, F.
Cieslak, D.
Graham, D.
Wang, C.
Menon, S.
Hendrikx, T.
Kanik, K. S.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 141 - 142
[3] Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors: OPAL Beyond, a Randomized, Double Blind, Placebo-Controlled, Phase 3 Trial
Gladman, Dafna D.
Rigby, William
Azevedo, Valderilio F.
Behrens, Frank
Blanco, Ricardo
Kaszuba, Andrzej
Kudlacz, Elizabeth
Wang, Cunshan
Menon, Sujatha
Hendrikx, Thijs
Kanik, Keith S.
[J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
[4] Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumor necrosis factor inhibitors: OPAL Beyond, a randomized, double blind, placebo-controlled, phase 3 trial
Gladman, Dafna
Rigby, William
Azevedo, Valderilio
Behrens, Frank
Blanco, Ricardo
Kaszuba, Andrzej
Wang, Cunshan
Menon, Sujatha
Hendrikx, Thijs
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB114 - AB114
[5] EFFICACY AND SAFETY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: OPAL BEYOND, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL
Gladman, D. D.
Rigby, W. F. C.
Azevedo, V. F.
Behrens, F.
Blanco, R.
Kaszuba, A.
Kudlacz, E.
Wang, C.
Menon, S.
Hendrikx, T.
Kanik, K. S.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 135 - 136
[6] Prediction of Response to Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis
de Vlam, Kurt
Coates, Laura
Ogdie, Alexis
Helliwell, Philip
van der Heijde, Desiree
Gladman, Dafna
Wang, Cunshan
Wu, Joseph
Fallon, Lara
[J]. JOURNAL OF RHEUMATOLOGY, 2019, 46 (07) : 848 - 848
[7] Integrated Efficacy Analysis of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis
Nash, Peter
Coates, Laura C.
Fleischmann, Roy
Papp, Kim
Gomez-Reino, Juan J.
Kanik, Keith S.
Wang, Cunshan
Wu, Joseph
Hendrikx, Thijs
Ports, William C.
[J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
[8] INTEGRATED EFFICACY ANALYSIS OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Nash, P.
Coates, L. C.
Fleischmann, R.
Papp, K. A.
Gomez-Reino, J. J.
Kanik, K. S.
Wang, C.
Wu, J.
Hendrikx, T.
Ports, W. C.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 951 - 952
[9] EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR)
Helliwell, P.
Van den Bosch, F.
Coates, L. C.
Gladman, D. D.
Tasset, C.
Meuleners, L.
Gilles, L.
Gheyle, L.
Trivedi, M.
Alani, M.
Besuyen, R.
Mease, P. J.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 761 - 762
[10] COMPARISON OF TOFACITINIB SAFETY AND EFFICACY IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DMARDS, OR TO ONE OR MORE BIOLOGICAL DMARDS
Charles-Schoeman, C.
Kremer, J.
Krishnaswami, S.
Soma, K.
Geier, J.
Zhang, R.
Strengholt, S.
Burmester, G.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 271 - 272

← 1 2 3 4 5 →